-
1 Comment
Yuhan Corporation is currently in a long term downtrend where the price is trading 0.1% below its 200 day moving average.
From a valuation standpoint, the stock is 70.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Yuhan Corporation's total revenue rose by 17.2% to $461B since the same quarter in the previous year.
Its net income has increased by 173.0% to $13B since the same quarter in the previous year.
Finally, its free cash flow fell by 161.7% to $-3B since the same quarter in the previous year.
Based on the above factors, Yuhan Corporation gets an overall score of 3/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | KR7000100008 |
| Sector | Healthcare |
| Market Cap | 9T |
|---|---|
| PE Ratio | None |
| Target Price | 152538.47 |
| Dividend Yield | 0.4% |
| Beta | 0.7 |
Yuhan Corporation manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally. It also manufactures and sells animal feed and health functional food. The company was founded in 1926 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 000100.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
